Patients and pathohistological data
| No of patients | 1 y survival rate (%) (95% CI) | Median (95% CI) survival (days) | OR (crude) | |
| All | 41 | 31 (17–45) | 210 (156–264) | |
| Stage1-c | ||||
| Stage I | 1/41 (5%) | 100 | Patient alive (after 1596 days) | 1-a |
| Stage II | 7/41 (15%) | 100 | 7 patients alive (after 257–1323 days) | |
| Stage IIIA | 21/41 (51%) | 24 (0–44) | 210 (134–286) | |
| Stage IIIB | 3/41 (7%) | 0 | 80 (48–112) | |
| Stage IVA | 9/41 (22%) | 0 | 89 (0–47) | |
| pT category1-c | ||||
| pT1/2 | 8/41 (20%) | 100 | All alive | |
| pT3/4 | 33/41 (80%) | 15 (3–27) | 159 (111–107) | 1-a |
| pN category1-c | ||||
| pNO | 32/41 (78%) | 40 | 251 (215–287) | |
| pN1 | 9/41 (22%) | 0 | 80 (56–104) | 8.4 (3.4–20.4) |
| Grading1-d | ||||
| G1 | 14/41 (34%) | 48 (21–75) | 369 | |
| G2 | 21/41 (51%) | 20 (4–36) | 156 (71–241) | 2.8 (1.2–6.5) |
| G3 | 6/41 (15%) | 17 (0–47) | 80 (0–174) | 3.7 (1.3–11.9) |
| K-rasmutation | ||||
| Yes | 22/41 (54%) | 24 (17–42) | 215 (145–261) | |
| No | 19/41 (46%) | 41 (32–69) | 291 (156–299) | 2.0 (1.2–3.2) |
| p16 methylation | ||||
| Yes | 34/41 (83%) | 28 (15–43) | 205 (123–269) | |
| No | 7/41 (17%) | 41 (16–45) | 235 (171–261) | NS |